Som med alle lægemidler mod hiv kan patienter, der tager Kaletra, have risiko for lipodystrofi (forandringer i kropsfedtets fordeling), osteonekrose (knoglevævsdød) eller immunt reaktivationssyndrom (symptomer på infektion, der er forårsaget af, at immunsystemet genvinder sin funktion).
As with all anti-HIV medicines, patients taking Kaletra may be at risk of lipodystrophy (changes in the distribution of body fat), osteonecrosis (death of bone tissue) or immune reactivation syndrome (symptoms of infection caused by the recovering immune system).